KalVista Pharmaceuticals (KALV) Tops Q1 EPS by 14c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q1 EPS of ($0.74), $0.14 better than the analyst estimate of ($0.88).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• DA Davidson Assumes Knife River Corp. (KNF) at Buy
• Raymond James: 'We now believe that 12 of the top 20 pharma companies have selected Veeva CRM'
• Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance